4.6 Article

A Bicuspid Aortic Valve Imaging Classification for the TAVR Era

期刊

JACC-CARDIOVASCULAR IMAGING
卷 9, 期 10, 页码 1145-1158

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2015.12.022

关键词

aortic stenosis; aortic valve replacement; bicuspid aortic valve; transcatheter aortic valve implantation; transcatheter aortic valve replacement; TAVI; TAVR

资金

  1. Edwards Lifesciences
  2. St. Jude Medical
  3. Medtronic
  4. Philips
  5. Philips Healthcare
  6. Abbott
  7. Access Closure
  8. AGA
  9. Angiomed
  10. Aptus
  11. Atrium
  12. Avinger
  13. Bard
  14. Boston Scientific
  15. Bridge point
  16. Carag
  17. Cardiac Dimensions
  18. Cardiokinetix
  19. CardioMEMS
  20. Cardiox
  21. Celonova
  22. CGuard
  23. Coherex
  24. Contego
  25. Covidien
  26. CSI
  27. CVRx
  28. EndoCross
  29. ev3
  30. FlowCardia
  31. Gardia
  32. Gore
  33. Guided Delivery Systems
  34. Hemoteq
  35. InSeal Medical
  36. Lumen Biomedical
  37. HLT
  38. Lifetech
  39. Lutonix
  40. Maya Medical
  41. NDC
  42. Occlutech
  43. Osprey
  44. Ostial
  45. PendraCare
  46. pfm Medical
  47. Recor
  48. ResMed
  49. Rox Medical
  50. SentreHeart
  51. Spectranetics
  52. SquareOne
  53. Svelte Medical Systems
  54. Trireme
  55. Trivascular
  56. Vascular Dynamics
  57. Venus Medical
  58. Veryan
  59. Vessix
  60. Cook
  61. Circl CVI

向作者/读者索取更多资源

OBJECTIVES This study sought to evaluate transcatheter aortic valve replacement (TAVR) in bicuspid aortic valve (BAV) aortic stenosis (AS), with a particular emphasis on TAVR-directed bicuspid aortic valve imaging (BAVi) of morphological classification. BACKGROUND TAVR has been used to treat BAV-AS but with heterogeneous outcomes and uncertainty regarding the relevance of morphology. METHODS In 14 centers in the United States, Canada, Europe, and Asia, 130 BAV-AS patients underwent TAVR. Baseline cardiac computed tomography (CT) was analyzed by a dedicated Corelab. Outcomes were assessed in line with Valve Academic Research Consortium criteria. RESULTS Bicommissural BAV (vs. tricommissural) accounted for 68.9% of those treated in North America, 88.9% in Europe, and 95.5% in Asia (p = 0.003). For bicommissural bicuspids, non-raphe type (vs. raphe type) BAV accounted for 11.9% of those treated in North America, 9.4% in Europe, and 61.9% in Asia (p < 0.001). Overall rates of 30-day mortality (3.8%) and cerebrovascular events (3.2%) were favorable and similar among anatomical subsets. The rate of new permanent pacemaker insertion was high (26.2%) and similar between balloon-expandable (BE) and self expanding (SE) designs (BE: 25.5% vs. SE: 26.9%; p = 0.83); there was a trend to greater permanent pacemaker insertion in BE TAVR in the presence of coronary cusp fusion BAV morphology. Paravalvular aortic regurgitation (PAR) moderate was 18.1% overall but lower at 11.5% in those with pre-procedural CT. In the absence of pre-procedural CT, there was an excess of PAR in BE TAVR that was not the case in those with a pre-procedural CT; SE TAVR required more post-dilation. Predictors of PAR included intercommissural distance for bicommissural bicuspids (odd ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02 to 1.84; p = 0.036) and lack of a baseline CT for annular measurement (OR: 3.03; 95% CI: 1.20 to 7.69; p = 0.018). CONCLUSIONS In this multicenter study, TAVR achieved favorable outcomes in patients with pre-procedural CT, with the exception of high permanent pacemaker rates for all devices and shapes. (C) 2016 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据